Topic: management changes
Sanofi went through quite a lot of changes in 2019, culminating in a brand-new strategy. Under CEO Paul Hudson, the company is steering toward therapeutic fields where it thinks it can lead and away from cardiovascular and diabetes.
Barclays M&A veteran Elizabeth Mily will take over as business development chief as BMS looks for long-term growth beyond Opdivo.
Sanofi is separating the role of chief digital officer, as CEO Paul Hudson rolls out a makeover partly aimed at boosting its technology capabilities.
The departure of BMS' Paul Biondi, who presided over an extensive deal-making strategy, adds to the challenges presented by the Celgene integration.
Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.
Sanofi CEO Paul Hudson hinted at a coming shakeup—from diabetes to cancer and R&D to marketing. And he's planning to unveil those plans December 10.
Pfizer executive chairman Ian Read, who handed off the CEO baton to Albert Bourla this year, will now step aside completely and retire at year's end.
Patient centricity may be a catchphrase, but with a new exec poached from Sanofi, Astellas is working to puts its money where its mouth is.
The former National Cancer Institute director reportedly has support from five ex-FDA commissioners, including his predecessor, Scott Gottlieb.
Salix Pharmaceuticals President Mark McKenna is leaving Bausch Health for a precision medicine company.